As the cannabis market continues to evolve and companies shift from pure-play cultivation to global consumer brands, choosing between Canopy Growth (NASDAQ:CGC) and Tilray Brands (NASDAQ:TLRY) hinges on weighing two distinct routes to profitability.
CGC pursues a refined cannabis strategy centered on the Canadian adult-use market, while pushing into pharmaceuticals through medical distribution in Europe. A sizable share of its revenue comes from supply contracts with all 12 Canadian provinces and territories, though these agreements carry no binding minimum purchase obligations, leaving customer concentration a source of risk.
TLRY, by contrast, positions itself as a global lifestyle consumer products company. It supplies pharmaceutical products to German pharmacies, distributes to more than 900 beverage wholesalers in the U.S., and has expanded into craft beverages and wellness to reduce its reliance on volatile cannabis prices. Its own provincial contracts in Canada likewise come with no minimum volume guarantees.
For FY2026, CGC generated revenue of nearly $199.5 million, up 5.8% year over year, but posted a net loss of about $184.3 million, compared with a $419.3 million loss in the prior year. Its operating margin stood at -92.4% and gross margin at 18.25%, with a debt-to-equity ratio of 0.4x, a current ratio of 3.3x, and free cash flow of roughly -$48.9 million. The company carries a market capitalization of $302 million and a P/S ratio of 1.5x.
TLRY reported FY2026 revenue of close to $915.5 million, down about 18.8%, alongside a net loss of roughly $122.6 million. Its net margin of -13.4% narrowed sharply from -266.3% in FY2025, while gross margin reached 26.82%. With a debt-to-equity ratio of 0.2x, a current ratio of 2.2x and free cash flow near -$102.1 million, TLRY holds a market capitalization of $464 million and a P/S ratio of 0.4x. Neither company has a meaningful Forward P/E, and TLRY trades at the lower sales multiple.
CGC recently identified a material weakness in its internal financial controls, prompting a restatement of prior data, and faces regulatory uncertainty around its Canopy USA expansion along with potential delisting threats. It has reported net losses every year since 2019.
TLRY must navigate steep regulatory hurdles and licensing requirements across dozens of jurisdictions, competes against rivals such as TerrAscend and the illicit market, and carries integration risks from acquisitions including BrewDog, while currency swings and dependence on third-party distributors add further pressure.
In Q1 of FY2027, TLRY delivered record revenue of $257 million, up 23% year over year, with gross profit growing faster; BrewDog turned profitable in the quarter and now self-finances. CGC, meanwhile, grew revenue 13% across every business segment, improved margins and narrowed losses, with management expecting positive adjusted EBITDA by year-end.
At an industry level, U.S. federal legalization keeps being delayed, mature markets face pricing pressure, and most companies continue to burn cash. The longer-term question for investors is not only whether either firm reaches profitability, but whether the cannabis market itself stabilizes enough to reward the patience holding either stock requires.
